Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine (SJTU-SM), Shanghai, China.
Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Cancer Sci. 2023 Jul;114(7):2882-2894. doi: 10.1111/cas.15822. Epub 2023 May 3.
ANP32B, a member of the acidic leucine-rich nuclear phosphoprotein 32 kDa (ANP32) family of proteins, is critical for normal development because its constitutive knockout mice are perinatal lethal. It is also shown that ANP32B acts as a tumor-promoting gene in some kinds of cancer such as breast cancer and chronic myelogenous leukemia. Herein, we observe that ANP32B is lowly expressed in B-cell acute lymphoblastic leukemia (B-ALL) patients, which correlates with poor prognosis. Furthermore, we utilized the N-myc or BCR-ABL -induced B-ALL mouse model to investigate the role of ANP32B in B-ALL development. Intriguingly, conditional deletion of Anp32b in hematopoietic cells significantly promotes leukemogenesis in two B-ALL mouse models. Mechanistically, ANP32B interacts with purine rich box-1 (PU.1) and enhances the transcriptional activity of PU.1 in B-ALL cells. Overexpression of PU.1 dramatically suppresses B-ALL progression, and highly expressed PU.1 significantly reverses the accelerated leukemogenesis in Anp32b-deficient mice. Collectively, our findings identify ANP32B as a suppressor gene and provide novel insight into B-ALL pathogenesis.
ANP32B 是酸性亮氨酸丰富核磷蛋白 32kDa(ANP32)家族蛋白的成员,对正常发育至关重要,因为其组成型敲除小鼠在围产期致死。研究还表明,ANP32B 在某些癌症(如乳腺癌和慢性髓性白血病)中作为促进肿瘤的基因发挥作用。在此,我们观察到 ANP32B 在 B 细胞急性淋巴细胞白血病(B-ALL)患者中低表达,与预后不良相关。此外,我们利用 N-myc 或 BCR-ABL 诱导的 B-ALL 小鼠模型来研究 ANP32B 在 B-ALL 发展中的作用。有趣的是,造血细胞中 Anp32b 的条件缺失显著促进了两种 B-ALL 小鼠模型中的白血病发生。在机制上,ANP32B 与富含嘌呤盒 1(PU.1)相互作用,并增强 B-ALL 细胞中 PU.1 的转录活性。PU.1 的过表达显著抑制了 B-ALL 的进展,高表达的 PU.1 显著逆转了 Anp32b 缺失小鼠中加速的白血病发生。总之,我们的研究结果确定 ANP32B 为抑癌基因,并为 B-ALL 的发病机制提供了新的见解。